Carmat : A number of details on the “Forfait Innovationâ€
>“Forfait Innovation†dossier validated - As for the temporary authorisations for use for drugs, several weeks ago Carmat received the green light from the French health authorities for the “Forfait Innovationâ€. This allows a technology to be made available for patients before market authorisation. Carmat’s artificial heart meets the various criteria required for such an application. Indeed, the eligibility criteria are based on the innovative nature of the device and...Carmat is focused on the research and development of an innovative product in the medical sector, developing an orthotopic and biocompatible artificial heart which is completely implantable, as well as its electrical power supply system and remote diagnosis system. Co. is developing a long-term therapeutic solution for patients who suffer from advanced bi-ventricular heart failure and who are not eligible for cardiac transplantation and who have exhausted all drug possibilties. Co. is still in the phase of research and development and thus do not generate any revenues.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.